Mablink: Mablink Bioscience, the next generation ADC company, raises 4 Million to move forward its ADC pipeline targeted at cancers with high unmet medical needs

Mablink Bioscience, a company developing the next generation of antibody-drug conjugates (ADC) through its proprietary hydrophilic drug-linker PSARlink platform, announces today the completion of a €4 Million Seed financing round led by Elaia Partners and along with Pertinence Invest 2 (Sofimac Innovation advised by Mérieux Equity Partners